ft.com/frontpage

UK

Change edition

Asia
Europe
India
Middle East
UK
US

All times are London time

Financial Times

Advanced search

Sign in Site tour Register Subscribe

Welcome Subscribe Your account Site tour Sign out

Username

Password

Forgot password?

Remember me on this computer

"Remember me" uses a cookie. View our Cookie Policy.

Home
UK
World
- Africa
- Asia-Pacific
  - Asia-Pacific
  - Afghanistan
  - China
  - India
  - Japan
  - North Korea
  - Pakistan
- Europe
  - Europe
  - Brussels
- Latin America & Caribbean
- Middle East & North Africa
- UK
- US & Canada
- The World blog
Companies
Markets
Global Economy
- Economic Calendar
- Money Supply
- Americas
- China
- EU
- India
- Middle East
- UK
- US
Lex
Comment
Management
Personal Finance
Life & Arts
- Arts
- FT Magazine
- Food & Drink
- House & Home
- Style
- Books
  - Books
  - Essay
  - Fiction
  - Non-Fiction
- Pursuits
- Travel
  - Travel
  - UK
  - North America
  - Europe
  - Asia & Australia
  - Africa
  - Americas
  - Luxury
  - Adventures
  - Winter Sports
  - Family
  - City Breaks
- How To Spend It

July 19, 2008 3:00 am

Teva gains edge in generics with its $7.5bn Barr deal

By Andrew Jack in London

You have viewed your allowance of free articles. If you wish to view more, click the button below.

Read this

Advertisement

Help
•Contact us
•About us
•Sitemap
•Advertise with the FT
•Terms & conditions
•Privacy policy
•Copyright
•NEWCookie policy

© The Financial Times Ltd 2012 FT and 'Financial Times' are trademarks of The Financial Times Ltd.

Printed from: http://www.ft.com/cms/s/97a290f4-552a-11dd-ae9c-000077b07658,Authorised=false.html

Print a single copy of this article for personal use. Contact us if you wish to print more to distribute to others.

© The Financial Times Ltd 2012 FT and ‘Financial Times’ are trademarks of The Financial Times Ltd. Privacy policy | Terms | Copyright